BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 37681903)

  • 21. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields).
    Shteingauz A; Porat Y; Voloshin T; Schneiderman RS; Munster M; Zeevi E; Kaynan N; Gotlib K; Giladi M; Kirson ED; Weinberg U; Kinzel A; Palti Y
    Cell Death Dis; 2018 Oct; 9(11):1074. PubMed ID: 30341282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
    Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
    JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
    Stupp R; Taillibert S; Kanner AA; Kesari S; Steinberg DM; Toms SA; Taylor LP; Lieberman F; Silvani A; Fink KL; Barnett GH; Zhu JJ; Henson JW; Engelhard HH; Chen TC; Tran DD; Sroubek J; Tran ND; Hottinger AF; Landolfi J; Desai R; Caroli M; Kew Y; Honnorat J; Idbaih A; Kirson ED; Weinberg U; Palti Y; Hegi ME; Ram Z
    JAMA; 2015 Dec; 314(23):2535-43. PubMed ID: 26670971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center.
    Chen C; Xu H; Song K; Zhang Y; Zhang J; Wang Y; Sheng X; Chen L; Qin Z
    J Clin Med; 2022 Oct; 11(19):. PubMed ID: 36233722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling.
    Wenger C; Miranda PC; Salvador R; Thielscher A; Bomzon Z; Giladi M; Mrugala MM; Korshoej AR
    IEEE Rev Biomed Eng; 2018; 11():195-207. PubMed ID: 29993870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study.
    Ali AS; Lombardo J; Niazi MZ; Miller RC; Alnahhas I; Martinez NL; Andrews DW; Judy KD; Shi W
    J Neurooncol; 2022 Nov; 160(2):345-350. PubMed ID: 36355259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy.
    Jo Y; Kim EH; Sai S; Kim JS; Cho JM; Kim H; Baek JH; Kim JY; Hwang SG; Yoon M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30469352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial.
    Guberina N; Pöttgen C; Kebir S; Lazaridis L; Scharmberg C; Lübcke W; Niessen M; Guberina M; Scheffler B; Jendrossek V; Jabbarli R; Pierscianek D; Sure U; Schmidt T; Oster C; Hau P; Grosu AL; Stuschke M; Glas M; Nour Y; Lüdemann L
    Radiat Oncol; 2020 Apr; 15(1):83. PubMed ID: 32307022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapy.
    Pohling C; Nguyen H; Chang E; Schubert KE; Nie Y; Bashkirov V; Yamamoto V; Zeng Y; Stupp R; Schulte RW; Patel CB
    Bioelectrochemistry; 2023 Feb; 149():108287. PubMed ID: 36306728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor Treating Fields in the Management of Patients with Malignant Gliomas.
    Ghiaseddin AP; Shin D; Melnick K; Tran DD
    Curr Treat Options Oncol; 2020 Jul; 21(9):76. PubMed ID: 32734509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor treating fields: a novel treatment modality and its use in brain tumors.
    Hottinger AF; Pacheco P; Stupp R
    Neuro Oncol; 2016 Oct; 18(10):1338-49. PubMed ID: 27664860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [
    Patel CB; Beinat C; Xie Y; Chang E; Gambhir SS
    Neoplasia; 2021 Jan; 23(1):58-67. PubMed ID: 33221711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis.
    Ballo MT; Conlon P; Lavy-Shahaf G; Kinzel A; Vymazal J; Rulseh AM
    J Neurooncol; 2023 Aug; 164(1):1-9. PubMed ID: 37493865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cilia at the Crossroads of Tumor Treating Fields and Chemotherapy.
    Deleyrolle LP; Sarkisian MR
    Dev Neurosci; 2023; 45(3):139-146. PubMed ID: 38630257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-Treating Fields in Glioblastomas: Past, Present, and Future.
    Guo X; Yang X; Wu J; Yang H; Li Y; Li J; Liu Q; Wu C; Xing H; Liu P; Wang Y; Hu C; Ma W
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor treating fields: a comprehensive overview of the underlying molecular mechanism.
    Hong P; Kudulaiti N; Wu S; Nie J; Zhuang D
    Expert Rev Mol Diagn; 2022 Jan; 22(1):19-28. PubMed ID: 34883030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complete radiological response following subtotal resection in three glioblastoma patients under treatment with Tumor Treating Fields.
    Kessler AF; Linsenmann T; Westermaier T; Wolber W; Weiland J; Monoranu CM; Breun M; Hagemann C; Ernestus RI; Löhr M
    Oncol Lett; 2020 Jan; 19(1):557-561. PubMed ID: 31897171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M - a case report.
    Gött H; Kiez S; Dohmen H; Kolodziej M; Stein M
    Childs Nerv Syst; 2022 Sep; 38(9):1791-1796. PubMed ID: 35181800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields.
    Pandey M; Xiu J; Mittal S; Zeng J; Saul M; Kesari S; Azadi A; Newton H; Deniz K; Ladner K; Sumrall A; Korn WM; Lou E
    Neurooncol Adv; 2022; 4(1):vdac096. PubMed ID: 35821680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.
    Turner SG; Gergel T; Wu H; Lacroix M; Toms SA
    World J Surg Oncol; 2014 May; 12():162. PubMed ID: 24884522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.